

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/r370

CME INFORMATION

Program Faculty

Course Director

Deepak L. Bhatt, MD

Cardiovascular Coordinating Center
Cleveland Clinic
Cleveland, Ohio

Stephen D. Wiviott, MD

Brigham and Women's Hospital
Harvard School of Medicine
Boston, Massachusetts

Eric R. Bates, MD

University of Michigan
Ann Arbor, Michigan

CME Reviewer

Allan Miller, MD

University of Florida College of Medicine
Gainesville, Florida



This CME activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education.



This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Eli Lilly and Company.

PVI, PeerView Institute for Medical Education, 315 Bleecker Street, Suite 182, New York, NY 10014
Copyright © 2000-2008, PeerView Press

To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/r370

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/r370

General Information

Requirements for Successful Completion:

In order to receive credit, participants must view all audiovisual presentations and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Certificates are awarded upon successful completion of the post-test and evaluation form.

Media: Internet

Release Date: March 7, 2008

Expiration Date: March 6, 2009

Estimated time to complete activity: 45 minutes

Sponsorship: This CME activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education.

Support: This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Eli Lilly and Company.

Faculty Disclosures/Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Deepak L. Bhatt, MD, has a financial interest/relationship or affiliation in the form of: *Consultant* for Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; Bayer Corporation; Bristol-Myers Squibb Company; Cardax Pharmaceuticals, Inc.; Centocor, Inc.; Cogentus Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; McNeil PDI Inc.; Medtronic, Inc.; Millennium Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; ParinGenix Inc.; PDL BioPharma, Inc.; Philips Pharmaceuticals Ltd.; Portola Pharmaceuticals, Inc.; sanofi-aventis; Schering-Plough Corporation; Scios Inc.; The Medicines Company; TNS Healthcare; and Vertex Pharmaceuticals Incorporated.

Grant/Research Support from Bristol-Myers Squibb Company; Eisai Inc.; Ethicon Inc.; HeartScape Technologies, Inc.; sanofi-aventis; and The Medicines Company (given directly to the Cleveland Clinic Cardiovascular Coordinating Center).

Speakers Bureau participant with Bristol-Myers Squibb Company; sanofi-aventis; and The Medicines Company (Dr. Bhatt has not been a Speakers Bureau participant for more than two years).

Honoraria from AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Centocor, Inc.; Eisai Inc.; Eli Lilly and Company; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.; ParinGenix Inc.; PDL BioPharma, Inc.; sanofi-aventis; Schering-Plough Corporation; The Medicines Company; and TNS Healthcare (donated to non-profit organizations for more than two years).

Other Financial or Material Support from Cleveland Clinic Cardiovascular Coordinating Center currently receives or has received research funding from Abraxis Oncology; Alexion Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; AtheroGenics, Inc.; Biosense Webster, Inc.; Biosite, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific Corporation; Bristol-Myers Squibb Company; CardioNet; Centocor, Inc.; Converge Medical, Inc.; Cordis Corporation; Dr. Reddy's Laboratories Ltd.; Edwards Lifesciences LLC; Esperion Therapeutics, Inc.; GE Medical Systems; Genentech, Inc.; Guilford Pharmaceuticals Inc.; GlaxoSmithKline; Guidant Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kensey Nash Corporation; Lilly Research Laboratories; Medtronic, Inc.; Merck & Co., Inc.; Mytogen, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Orphan Therapeutics, LLC; Pfizer, Inc.; Procter & Gamble; Roche Laboratories Inc.; Sankyo Co., Ltd.; sanofi-aventis; Schering-Plough Corporation; Scios Inc.; St. Jude Medical, Inc.; Takeda Pharmaceuticals North America, Inc.; TMC Pharmaceuticals International, Inc.; VasoGenix Pharmaceuticals, Inc.; and Viacor, Inc.

To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/r370

Preventing Thrombotic Complications After Percutaneous Coronary Intervention: An Update for Cardiologists

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/r370

Stephen D. Wiviott, MD, has a financial interest/relationship or affiliation in the form of: Consultant for Arena Pharmaceuticals, Inc. and sanofi-aventis. Grant/Research Support from Daiichi Sankyo, Inc. and Eli Lilly and Company.

Eric R. Bates, MD, has a financial interest/relationship or affiliation in the form of: Consultant for Eli Lilly and Company; sanofi-aventis; and The Medicines Company. Grant/Research Support from Eli Lilly and Company. Speakers Bureau participant with Eli Lilly and Company; sanofi-aventis; and Schering-Plough Corporation.

CME Reviewer: Allan Miller, MD, has a financial interest/relationship or affiliation in the form of: Grant/Research Support from AstraZeneca Pharmaceuticals LP; Gilead Sciences, Inc.; GlaxoSmithKline; Medtronic, Inc.; Myogen, Inc.; NitroMed, Inc.; NovaCardia, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc. Speakers Bureau participant with AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; CV Therapeutics, Inc.; GlaxoSmithKline; King Pharmaceuticals Inc.; Medtronic, Inc.; NitroMed, Inc.; Pfizer Inc.; sanofi-aventis; and Wyeth Pharmaceuticals Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Target Audience

This activity has been designed to meet the educational needs of cardiologists.

Program Description

In this activity, experts in the management of acute coronary syndrome (ACS) describe the rationale and updated guidelines supporting the long-term use of dual antithrombotic therapy in patients who have undergone percutaneous coronary intervention (PCI) with stent placement. In addition, limitations regarding the pharmacokinetics of clopidogrel in this context lay the foundation for the discussion of novel antithrombotic agents in development.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Describe the benefits and risks of stenting associated with percutaneous coronary intervention (PCI) and recommended antithrombotic regimens to reduce associated risks
- Identify the pharmacokinetic limitations of clopidogrel in the context of PCI and discuss the development of novel antithrombotic agents that may address these limitations
- Describe clinical factors increasing the risk of stent-related thrombosis and management strategies to reduce this risk

To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/r370

Participate in the CME-certified multimedia activity featured in this podcast.
Go online now at:

www.peerviewpress.com/pc2/r370

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Florida College of Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements

PeerView Press requires version 6.x browsers or higher from Microsoft or Netscape. Certain activities may require additional software to view. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Reader®, and Adobe® Flash Player.

Privacy Policy

PeerView Press shares your concerns about maintaining the privacy of personal information collected on the Internet. PeerView Press ensures that confidentiality of data relating to individual visitors to a medical/health web site, including their identity, is respected by this web site. The web site owners undertake to honor or exceed the legal requirements of medical/health information privacy that apply in the country and state where the web site and mirror sites are located.

Privacy Policy Changes:

Minor changes to our privacy policy may occur. If privacy policies change in a way that significantly affects the way we handle personal information, we will not use the information we have previously collected without obtaining consent. We will post all privacy policy changes on our web site in a timely manner.

Collection of Personal Information from Site Users:

Visitors to PeerView Press can access and browse the site, without disclosing any personally identifiable information. PeerView Press does track some information provided by your browser, such as the time and date of access, the web site you came from, the type of browser used, and other information that does not personally identify you. Visitors registering for services such as email updates, or completing program evaluation forms are requested to provide personal information, such as name, contact information, and medical specialty. We clearly label which information is required for registration, and which information is optional, on our registration forms. PeerView Press will not collect personally identifiable information without consent and will not share this data with any external partners.

[Click here to see the full PeerView Press Privacy Policy](#)

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**To complete the post-test and evaluation for CME credit
please click here: www.peerviewpress.com/pc2/r370**